Research
Hormonal
Retatrutide resulted in a percentage change in weight from baseline to 24 weeks ranging from -7.2% to -~18% as the dose increased from 1 mg to 12 mg.
Retatrutide may be an effective treatment option for weight loss in individuals with obesity.
StrongSupportsmedium confidence
The primary end point was percentage change in weight from baseline to 24 weeks, which ranged from -7.2% to -~18% as the dose of retatrutide increased from 1 mg to 12 mg.
Why this rating
Based on the phase 2 clinical trial design mentioned in the abstract.
Source
Retatrutide showing promise in obesity (and type 2 diabetes)
Sheila A Doggrell · Expert Opinion on Investigational Drugs · 2023
DOI 10.1080/13543784.2023.2283020
otherCited 14×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →